RECRUITING

Evaluation of the Electronic Cigarette Withdrawal Syndrome

Talk to us

Conditions

E-cigarette UseWithdrawal

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.

Official Title

Evaluation of the Electronic Cigarette Withdrawal Syndrome: Mechanistic Targets for Intervention

Quick Facts

Study Start:2023-11-28
Study Completion:2028-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06066996

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. 21-55 years old
  2. 2. good general health as reviewed by study medical team
  3. 3. vital signs in normal range as reviewed by study medical team
  4. 4. negative urine test for illicit drug use (excluding THC) and negative breath alcohol test
  5. 5. daily use of a nicotine-containing e-cigarette for at least 6 months
  6. 6. no regular use of other tobacco products (e.g., smokeless products) for at least 6 months
  7. 7. urine cotinine \>100ng/mL (i.e., recommended cutoff for confirming current nicotine use)
  8. 8. exhaled breath carbon monoxide (CO) \<6ppm
  9. 9. Penn State E-cigarette Dependence (PSED) score \>=4, indicating mild dependence or greater
  10. 10. have an interest in reducing e-cigarette use
  1. 1. psychoactive drug use (aside from cannabis, nicotine, alcohol, caffeine) in past month
  2. 2. current use of over-the-counter (OTC) or prescription medications that may impact safety
  3. 3. use cannabis \>2 times per week
  4. 4. history of or current significant medical condition that would impact participation or safety according to the study investigators and medical staff
  5. 5. current psychiatric condition or substance use disorder (aside from tobacco use disorder) that would impact participation or safety according to the study investigators and medical staff
  6. 6. enrollment in another trial
  7. 7. positive pregnancy test
  8. 8. currently using a nicotine/tobacco cessation product
  9. 9. seizure disorder or traumatic brain injury (TBI)

Contacts and Locations

Study Contact

Justin Strickland, Ph.D.
CONTACT
4105501975
jstric14@jhmi.edu

Principal Investigator

Justin Strickland, Ph.D.
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

Behavioral Pharmacology Research Unit
Baltimore, Maryland, 21224
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Justin Strickland, Ph.D., PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-28
Study Completion Date2028-08-31

Study Record Updates

Study Start Date2023-11-28
Study Completion Date2028-08-31

Terms related to this study

Additional Relevant MeSH Terms

  • E-cigarette Use
  • Withdrawal